ArticleCureus2026
Mitomycin C-Based Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Colorectal Cancer With Peritoneal Metastasis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) with peritoneal metastasis is associated with poor prognosis despite advances in systemic chemotherapy and targeted therapies. Hyperthermic intraperitoneal chemotherapy (HIPEC) aims to eradicate free cancer cells within the peritoneal cavity and may improve survival outcomes. This study evaluated the efficacy and safety of mitomycin C (MMC)-based HIPEC in patients with CRC and isolated peritoneal metastasis.
methodsPatients with CRC and peritoneal metastasis treated between November 2018 and January 2024 were retrospectively reviewed. Patients undergoing CRS followed by MMC-based HIPEC were compared with those managed without HIPEC. Clinicopathologic characteristics, perioperative outcomes, postoperative morbidity, and oncologic outcomes were analyzed.
resultsA total of 48 patients were included. The mean intraoperative Peritoneal Cancer Index was 9 (range, 2-33). Complete cytoreduction 0 was achieved in 29 patients (93.5%) who underwent CRS and HIPEC. Postoperative complications occurred in 10 patients (20.8%), with anastomotic leakage requiring reoperation in four patients (8.3%). Median overall survival was significantly longer in the HIPEC group compared with the non-HIPEC group (54.2 vs. 24.5 months, HR 0.30; 95% confidence interval [CI], 0.15-0.61; p < 0.001). The five-year overall survival rate was 47.9% in the HIPEC group vs. 4.9% in the non-HIPEC group. Median progression-free survival following HIPEC was 29.6 months (95% CI, 24.2-34.8). HIPEC was significantly associated with improved overall survival on multivariable analysis.
conclusionCRS combined with MMC-based HIPEC provides a significant survival benefit for selected patients with colorectal cancer and isolated peritoneal metastasis. These findings support the role of MMC-based HIPEC as an effective locoregional treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.